BRISTOL MYERS SQUIBB CO (BMY)
Health Care / Pharmaceuticals
S&P 500$54.00
Middle of the pack. No strong signal either way.
Consider Buy
Score based on 4 of 5 models — moderate confidence
Is BRISTOL MYERS SQUIBB CO a Good Investment in 2026?
BRISTOL MYERS SQUIBB CO (BMY) scores 5.8 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates BRISTOL MYERS SQUIBB CO as Strong (8/9). However, the Graham model rates it Caution — Significantly above fair value. BRISTOL MYERS SQUIBB CO ranks #308 out of 1123 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Valuation
Trades at 16x earnings — near sector median of 26x.
Fair value estimate not available for this stock.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Strong
8/9
Buffett
Attractive
Business quality & competitive moat
Graham
Caution
Significantly above fair value
Lynch
Neutral
Growth rate vs price (PEG)
Greenblatt
Attractive
Top 25% (rank 13%)
Frequently Asked Questions
Is BRISTOL MYERS SQUIBB CO (BMY) a good investment?
What is BRISTOL MYERS SQUIBB CO's Piotroski F-Score?
Is BMY overvalued or undervalued?
How does BMY compare to other Health Care stocks?
What do investment models say about BMY?
Similar Stocks
Compare BMY with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer